Cargando…

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma

PURPOSE: Neuroblastoma (NB) is the most frequent extracranial tumor in children. The detection of bone marrow (BM) involvement is crucial for correct staging and risk-adapted treatment. We compared three methods regarding the detection of NB involvement in BM. METHODS: Eighty-one patients with NB we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schriegel, Felix, Taschner-Mandl, Sabine, Bernkopf, Marie, Grunwald, Uwe, Siebert, Nikolai, Ambros, Peter F., Ambros, Inge, Lode, Holger N., Henze, Guenter, Ehlert, Karoline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9470647/ https://www.ncbi.nlm.nih.gov/pubmed/34623519 http://dx.doi.org/10.1007/s00432-021-03780-7

Ejemplares similares

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging
por: Lazic, Daria, et al.
Publicado: (2021)

Management of tumor rupture and abdominal compartment syndrome in an infant with bilateral high risk stage 4 neuroblastoma: A case report
por: Lode, Holger N., et al.
Publicado: (2019)

Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression
por: Rifatbegovic, Fikret, et al.
Publicado: (2017)

Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics
por: Ambros, Inge M., et al.
Publicado: (2014)

Enriched Bone Marrow Derived Disseminated Neuroblastoma Cells Can Be a Reliable Source for Gene Expression Studies—A Validation Study
por: Rifatbegovic, Fikret, et al.
Publicado: (2015)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Metronomic topotecan impedes tumor growth of MYCN-amplified neuroblastoma cells in vitro and in vivo by therapy induced senescence
por: Taschner-Mandl, Sabine, et al.
Publicado: (2015)

Bone marrows from neuroblastoma patients: An excellent source for tumor genome analyses
por: Abbasi, M. Reza, et al.
Publicado: (2014)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
por: Lode, Holger N., et al.
Publicado: (2023)

Neuroblastoma and the epigenome
por: Fetahu, Irfete S., et al.
Publicado: (2021)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
por: Klingel, Leah, et al.
Publicado: (2022)

An annotated fluorescence image dataset for training nuclear segmentation methods
por: Kromp, Florian, et al.
Publicado: (2020)

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup
por: Martinez-Monleon, Angela, et al.
Publicado: (2022)

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
por: Troschke-Meurer, Sascha, et al.
Publicado: (2019)

Human repair‐related Schwann cells adopt functions of antigen‐presenting cells in vitro
por: Berner, Jakob, et al.
Publicado: (2022)

Tumor Touch Imprints as Source for Whole Genome Analysis of Neuroblastoma Tumors
por: Brunner, Clemens, et al.
Publicado: (2016)

Single-cell transcriptomics and epigenomics unravel the role of monocytes in neuroblastoma bone marrow metastasis
por: Fetahu, Irfete S., et al.
Publicado: (2023)

Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8
por: Weiss, Tamara, et al.
Publicado: (2021)

VP2: Schwann Cells Regulate Neuronal Differentiation by Epidermal Growth Factor-Like Protein 8
por: Weiss, Tamara, et al.
Publicado: (2022)

Modulation of multidrug resistance proteins by statins in human neuroblastoma
por: Sieczkowski, Evelyn, et al.
Publicado: (2008)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

The genetic tumor background is an important determinant for heterogeneous MYCN‐amplified neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2016)

In vitro and in vivo profiling of P-glycoprotein in human neuroblastoma and rhabdomyosarcoma cells under simvastatin exposure
por: Sieczkowski, Evelyn, et al.
Publicado: (2009)

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study
por: Berbegall, Ana P., et al.
Publicado: (2018)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
por: Marx, Madlen, et al.
Publicado: (2018)

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee
por: Ambros, P F, et al.
Publicado: (2009)

Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma
por: Italia, Matteo, et al.
Publicado: (2023)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome
por: Hartlieb, Sabine A., et al.
Publicado: (2021)

Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1)
por: Bellini, Angela, et al.
Publicado: (2021)

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma
por: Bogen, Dominik, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nq7bltnk6r7ii8ng2499cjkbku